Home Shop Science About View Cart →
Home › Fat Loss › Retatrutide
Triple Agonist · SubQ 99%+ Purity Retatrutide
Fat Loss Most Popular

Retatrutide

Retatrutide — triple GIP/GLP-1/glucagon agonist with the most potent clinical weight loss signal observed in a peptide therapeutic to date.

★★★★☆ 4.7 · 52 verified reviews · See all
Price range: $46.00 through $300.00
Clear
🚚 Free expedited shipping on orders over $100 CAD · Estimated delivery: 2–4 business days
🔬 Third-Party Tested
🇨🇦 Ships Canada-Wide
📦 Discreet Packaging
🛡 Satisfaction Guarantee
Key Benefits
  • Activates GIP, GLP-1, and glucagon receptors — three-axis metabolic engagement
  • Phase 2 data: 24% mean body weight reduction at 24 weeks at the highest dose
  • Glucagon receptor activation directly drives hepatic fat oxidation and energy expenditure
  • Reduces visceral adiposity, liver fat, and triglycerides simultaneously
  • Weekly subcutaneous injection with sustained multi-pathway satiety
Community Insights

Why people research Retatrutide

These are the specific situations and goals that lead researchers to Retatrutide. For research purposes only.

01
Breaking through a plateau that tirzepatide couldn't overcome after months of no progress
02
Clearing stubborn visceral fat and fatty liver (MASLD/NASH)
the glucagon component targets liver fat uniquely
03
Achieving the most aggressive possible fat loss when dual agonists have been maxed out
04
Tackling metabolic syndrome across multiple markers simultaneously
triglycerides, visceral fat, blood pressure, and insulin resistance
05
Running a personal n=1 biohacker experiment on the most potent GLP-1 class peptide in current research
06
Increasing resting metabolic rate through glucagon receptor activation
a thermogenic effect the other GLP-1s lack
07
Body recomposition in physique athletes post-competition
aggressive fat loss with muscle signal preserved
08
Managing severe obesity with multiple comorbidities when earlier GLP-1 steps were insufficient
09
Reducing MASH/fatty liver
attracted by phase 2 data showing up to 82% liver fat reduction
10
Pushing past the perceived ceiling of tirzepatide toward the deeper weight loss numbers seen in trials
Protocol Builder

Dosage Calculator

Reference dosing by experience level. For research use only — always consult a licensed healthcare provider.

Suggested Dose
—
Select experience level and click Show Protocol
Reconstitution Guide
—
Based on 5mg vial + 2mL BAC water
Suggested Cycle Length
12–24 weeks
For research reference only

⚠ For research reference only. Retatrutide is not approved for human use. Always consult a qualified healthcare professional.

In Every Order

What's in the Box

Every Poptides order arrives in premium packaging, ready to use.

💊

Retatrutide Vial

Your selected amount of lyophilized Retatrutide in a sealed, sterile glass vial with silver crimp cap. COA included on request.

💧

BAC Water 3mL

Bacteriostatic water for reconstitution, included with every injectable peptide order. Maintains sterility for multi-dose use.

💉

Syringe Kit

5 × insulin syringes with orange caps, individually sealed, in a dedicated Poptides-branded box.

📋

Research Guide Card + Thank You Note

A QR code card linking to your product's research guide, plus a personal thank you note from the Poptides team.

📦

Discreet Outer Packaging

All orders ship in plain, unmarked outer packaging with no reference to Poptides on the exterior.

Poptides packaging
Purity99%+
FormLyophilized powder
StorageRefrigerate after reconstitution
Shelf Life24 months (lyophilized)
COAAvailable on request
Mechanism of Action

How Retatrutide Works

The mechanism of action, step by step.

01

Triple Receptor Co-Agonism

Retatrutide simultaneously activates GIP, GLP-1, and glucagon receptors — three incretin and counterregulatory hormone pathways — producing a broader and more potent metabolic effect than any single or dual agonist.

02

Glucagon-Driven Energy Expenditure

Glucagon receptor activation increases hepatic glucose output and thermogenesis, directly raising energy expenditure — a mechanism absent in GLP-1 and dual GIP/GLP-1 agents that contributes to retatrutide's superior fat loss.

03

Hepatic Fat Reduction

The glucagon component drives preferential mobilisation of hepatic lipid stores, reducing liver fat content (NAFLD/MASH) to a greater degree than GLP-1 monotherapy.

04

Appetite and Satiety Integration

GIP and GLP-1 receptor engagement in the hypothalamus and brainstem suppresses appetite circuits and slows gastric emptying, while glucagon signalling further reduces central hunger drive.

Dosing Protocols

Research Protocol

Published preclinical dosing guidelines for reference.

Starting Dose
2 mg
Once weekly, 4-week hold
Escalation
4–12 mg
Titrate by 2 mg every 4 weeks
Max Studied
12 mg
Highest dose in Phase 2 trials
Titration
8–24 weeks
Gradual escalation to target dose
Active Phase
6–12 months
Continued weight loss observed throughout
Monitoring
Every 8 weeks
Track glucose, lipids, liver enzymes
Peer-Reviewed Research

The Science Behind It

Peer-reviewed research supporting the mechanism of Retatrutide.

1

Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, for people with type 2 diabetes (Phase 2)

At 24 weeks, retatrutide 12 mg produced a 17.5% reduction in body weight in participants with type 2 diabetes, with significant reductions in HbA1c, triglycerides, and liver fat.

Lancet, 2023
2

Retatrutide for obesity — Phase 2 dose-finding trial

In adults with obesity, retatrutide 12 mg weekly produced a mean weight loss of 24.2% at 48 weeks, exceeding the efficacy of all previously approved anti-obesity agents in comparable timeframes.

New England Journal of Medicine, 2023
3

Glucagon receptor contribution to weight loss in triple-axis agonists

The inclusion of glucagon receptor activity in retatrutide was shown to increase resting energy expenditure and preferentially mobilise hepatic and visceral fat beyond what dual GIP/GLP-1 agonism achieves alone.

Cell Metabolism, 2023
Verified Purchases

Customer Reviews

Verified purchases from Canadian customers.

4.7
★★★★☆
Based on 3 reviews
5★
67%
4★
33%
3★
0%
2★
0%
1★
0%
S
Scott R.
Vancouver, BC · Weight Loss
★★★★★
✓ Verified Purchase
The most powerful thing I have tried

I had good results on tirzepatide but switched to retatrutide for research. The appetite suppression is noticeably stronger and I am down 28 lbs in 3.5 months. Titrated very slowly.

L
Lisa W.
Toronto, ON · Metabolic Health
★★★★★
✓ Verified Purchase
Visceral fat melting off

My waist measurement has dropped 4 inches in 14 weeks. Bloodwork at 10 weeks showed triglycerides down 40% and liver enzymes normalized. Results are impressive.

B
Brendan K.
Calgary, AB · Weight Loss
★★★★☆
✓ Verified Purchase
Requires careful titration

Started at 2 mg and took 12 weeks to reach 8 mg. The GI effects at higher doses are real — going slow made a big difference. Results at 8 mg are outstanding.

Common Questions

Frequently Asked Questions

Retatrutide is currently in Phase 3 clinical trials and is not yet approved as a pharmaceutical. Poptides supplies it for research purposes.
Retatrutide adds glucagon receptor agonism to the dual GIP/GLP-1 profile of tirzepatide. Phase 2 data shows approximately 24% weight loss versus tirzepatide's 21%, with superior reductions in liver fat and energy expenditure increases from the glucagon component.
Glucagon directly increases hepatic glucose production and thermogenesis, raising basal metabolic rate. This is a mechanism absent in GLP-1 and dual GIP/GLP-1 agents and accounts for retatrutide's additional fat loss.
Starting at 2 mg and holding for 4 weeks before each increase is strongly recommended. The combination of three receptor pathways produces stronger GI effects than dual agonists — patience during titration significantly improves tolerability.
The glucagon component can increase blood glucose in isolation, but this is offset by the GLP-1 and GIP insulinotropic effects. Monitoring fasting glucose and liver enzymes periodically is prudent.
Yes. MOTS-c or 5-Amino-1MQ address complementary NAD+/AMPK pathways and are commonly stacked. BPC-157 is sometimes added to support GI tolerance during the titration phase.
Retatrutide Retatrutide
Price range: $46.00 through $300.00